Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (Q24242674)

object named as

George A Wells

0 references

Ann Cranney

object named as

Ann Cranney

0 references

Doug Coyle

object named as

Doug Coyle

0 references

author name string

Joan Peterson

0 references

Michel Boucher

Cochrane Database of Systematic Reviews

0 references

publication date

23 January 2008

0 references

published in

0 references

cites work

A 2-Year Phase II Study with 1-Year of Follow-up of Risedronate (NE-58095) in Postmenopausal Osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Efficacy of risedronate on clinical vertebral fractures within six months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Risedronate prevents new vertebral fractures in postmenopausal women at high risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

An assessment tool for predicting fracture risk in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

The statistical basis of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Should meta-analysts search Embase in addition to Medline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Risk of Mortality Following Clinical Fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

The diagnosis of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

7 January 2021

Epidemiology of vertebral fractures in women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

7 January 2021

Population-based study of survival after osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

7 January 2021

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004523.PUB3

1 reference

7 January 2021